Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Stem cell therapy modulates inflammasome signaling in stroke: Possible involvement of Mitochondria?
Cerebrovascular Disease and Interventional Neurology
P16 - Poster Session 16 (5:30 PM-6:30 PM)
4-016

Our aim is to explore whether intra-arterial (IA) MSCs can inhibit production of NLRP1 by mitigating ASIC1a expression to render neuroprotection and further to explore if it influences  mitochondria transfer from stem cells to hypoxic neuronal cells.

Stroke is the second leading cause of death and disability worldwide. Acidosis following ischemia, worsens the pathology by activating the acid sensing ion channel 1a (ASIC1a). This activated ASIC1a increases the expression of NLRP1 inflammasome in a pH dependent manner that further activates the inflammatory cascade. ASIC1a then triggers the influx of Ca2+ ions, overload of which contributes to neuronal injury in ischemic stroke. Inflammasome causes mitochondrial dysfunction and also modulates mitochondrial transfer.Cell based therapy with mesenchymal stem cells (MSCs) is a promising approach for clinical translation and reported to act on inflammasomes and mitochondrial dysfunction. 

Ovariectomized Sprague Dawley rats were infused with IA MSCs at 6 hours post middle cerebral artery occlusion (MCAo) followed by 24 hours of reperfusion. Rats were evaluated for motor functions and neurodeficits. Brains were harvested for infarct size estimation, biochemical analysis and western blot experiments.

IA MSCs when given at a dose of 1x105 cells at 6 hours following ischemia confers neuroprotection as evident by the reduction in infarct volume, improvement in motor function and neurodeficits. An increase in GSH levels and concomitant reduction in elevated nitrite and MDA levels were observed in the IA MSCs treated animals. Expression of ASIC1a, NLRP1, NLRP3, ASC1, IL1β and caspase-1 were reduced following IA MSCs infusion in the cortical brain regions following ischemia Further, our preliminary in vitro studies have revealed transfer of mitochondria from stem cells to hypoxic neuronal cells and has involvement of inflammasome signaling in this process.

 

IA MSCs modulate ASIC1a mediated NLRP1 expression and influence mitochondrial transfer to confer neuroprotection in ischemic stroke.

Authors/Disclosures
Pallab Bhattacharya, PhD (National Institute of Pharmaceutical Âé¶¹´«Ã½Ó³»­ and Research (NIPER),Ahmedabad.)
PRESENTER
Dr. Bhattacharya has nothing to disclose.
Deepaneeta Sarmah, M Pharm (National Institute of Pharmaceutical Âé¶¹´«Ã½Ó³»­ and Research-Ahmedabad (NIPER-A)) Miss Sarmah has nothing to disclose.
No disclosure on file
Harpreet Kaur, MD (East Portland Neurology) No disclosure on file
No disclosure on file
Dileep R. Yavagal, MD, FÂé¶¹´«Ã½Ó³»­ (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.